

12 April 2022

(22-2970) Page: 1/2

## **Committee on Technical Barriers to Trade**

## Original: English

## **NOTIFICATION**

The following notification is being circulated in accordance with Article 10.6

1. Notifying Member: BRAZIL

If applicable, name of local government involved (Article 3.2 and 7.2):

2. Agency responsible:

Brazilian Health Regulatory Agency (ANVISA)

Name and address (including telephone and fax numbers, email and website addresses, if available) of agency or authority designated to handle comments regarding the notification shall be indicated if different from above:

National Institute of Metrology, Quality and Technology (INMETRO)

Telephone: +(55) 21 2145.3817 Telefax: +(55) 21 2563.5637

Email: barreirastecnicas@inmetro.gov.br

Web-site: www.inmetro.gov.br/barreirastecnicas

- 3. Notified under Article 2.9.2 [X], 2.10.1 [ ], 5.6.2 [ ], 5.7.1 [ ], 3.2 [ ], 7.2 [ ], other:
- 4. Products covered (HS or CCCN where applicable, otherwise national tariff heading. ICS numbers may be provided in addition, where applicable): HS (3003-3004) Medicaments
- **5. Title, number of pages and language(s) of the notified document:** Normative Instruction number 137, 30 March 2022; (12 page(s), in Portuguese)
- **6. Description of content:** This normative instruction contains provisions on Good Manufacturing Practices complementary to Blood-derived Medicines.
- 7. Objective and rationale, including the nature of urgent problems where applicable: Protection of human health or safety
- 8. Relevant documents:

-

**9. Proposed date of adoption:** 2 May 2022

Proposed date of entry into force: 2 May 2022

10. Final date for comments: Not applied

Texts available from: National enquiry point [ ] or address, telephone and fax numbers and email and website addresses, if available, of other body: 11.

Brazilian Health Regulatory Agency (Anvisa)SIA, Trecho 5, Área Especial 57

Brasília – DF / Brazil CEP: 71.205-050

Phone.: +(55) 61 3462.5402 Website: www.anvisa.gov.br